Loading organizations...
Diagnostics company developing non-endoscopic tests for early detection of oesophageal cancer and Barrett’s oesophagus, using AI.
Cyted is a Cambridge, UK-based healthcare company that develops non-endoscopic diagnostics and artificial intelligence-driven pathology platforms for the early detection of gastrointestinal diseases like oesophageal cancer. Operating with a workforce of 51 to 200 employees, the enterprise generates between $10 million and $50 million in estimated annual revenue across its clinical operations. The company recently secured US FDA clearance for its proprietary EndoSign capsule sponge test, having already delivered over 16,000 tests and processed more than 25,000 patient samples to date. Backed by a recent $44 million Series B funding round led by Morningside Venture Capital, the firm collaborates with prominent healthcare and technology organizations including Microsoft Research, Cancer Research UK, and the NHS. Cyted was founded in 2018 by Dr. Marcel Gehrung alongside a team of scientists and clinicians from the University of Cambridge.
Cyted has raised $77.7M across 3 funding rounds.
Cyted has raised $77.7M in total across 3 funding rounds.
Cyted Health is a gastrointestinal health company founded in 2020 that develops a non-endoscopic diagnostic platform for early detection of esophageal diseases, including pre-cancerous conditions like Barrett's Esophagus and esophageal cancer.[1][2][4] Its core product, EndoSign®, is an FDA 510(k)-cleared capsule sponge device for minimally invasive esophageal cell collection, paired with advanced biomarker molecular testing and AI-driven analysis to enable accessible screening and monitoring.[2][4][5] Cyted serves healthcare providers, patients at risk for esophageal conditions, and pharma/life sciences partners, addressing the problem of low diagnosis rates—fewer than 10% of Barrett's Esophagus cases are identified pre-cancer—where only 1 in 5 esophageal cancer patients survive.[4] The company has raised $30.1M previously and $44M in Series B financing in August 2025 to fuel US expansion, UK consolidation, and new tests, showing strong growth with ongoing clinical studies like DETECT-ME (US enrollment since March 2025).[1][2][4]
Cyted was founded in 2020 by leading experts at the University of Cambridge, including CEO and co-founder Marcel Gehrung, emerging from research into minimally invasive cell collection and proprietary biomarker discovery for esophageal conditions.[2][4] The idea stemmed from the need to transform detection of pre-cancerous, cancerous, and inflammatory esophageal diseases, leveraging capsule sponge technology to make diagnostics faster, less invasive, and more scalable than traditional endoscopy.[1][5] Early traction included UK commercial success, incubation/accelerator stages, and pivotal FDA clearance for EndoSign®, setting the stage for global expansion; by 2025, it secured Series B funding backed by EQT Life Sciences and the British Business Bank, with endorsements from figures like Science Minister Lord Vallance highlighting its university-to-market impact.[1][2]
Cyted rides the wave of AI-enhanced precision diagnostics and non-invasive cancer screening, targeting the fastest-growing esophageal cancer amid rising GI disease burdens, where early detection could slash mortality.[4][5] Timing aligns with post-2020 medtech funding resurgence and FDA nods for capsule tech, amplified by market forces like aging populations, telemedicine growth, and pharma demand for biomarkers in trials.[2][5] It influences the ecosystem by partnering with universities, NHS-like systems, and investors like EQT, pushing capsule sponges into frontline care and enabling population-scale screening (e.g., BEST4's 140,000 patients), potentially redefining GI standards beyond endoscopy giants.[2][5]
Cyted is poised to dominate non-endoscopic esophageal diagnostics, with US commercialization via DETECT-ME results, portfolio expansion, and Series B-fueled hires driving 2026 growth.[2][4] Trends like AI biomarker acceleration and value-based care will amplify its edge, evolving it from UK pioneer to global leader—potentially capturing a slice of the $10B+ GI diagnostics market. Watch for pharma integrations and BEST4 outcomes to cement its life-saving trajectory, transforming "earlier matters" from slogan to standard.[4][5]
Cyted has raised $77.7M in total across 3 funding rounds.
Cyted's investors include Carmine Circelli, Bruno Holthof, Advent Life Sciences, EQT Life Sciences, General Catalyst, BGF, HCA, Morningside, Lucy Edwardes Jones, Anthony Aiudi, NHS, Business Growth Fund.
Cyted has raised $77.7M across 3 funding rounds. Most recently, it raised $44.0M Series B in August 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2025 | $44.0M Series B | Carmine Circelli, Bruno Holthof | Advent Life Sciences, EQT Life Sciences, General Catalyst, BGF, HCA, Morningside |
| May 19, 2023 | $16.7M Grant / Other Equity | Lucy Edwardes Jones, Anthony Aiudi | NHS |
| May 1, 2023 | $17.0M Series A | Business Growth Fund, General Catalyst |